Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity
https://doi.org/10.14341/2072-0351-5643
Abstract
Aim.
To study efficacy of treatment with liraglutide in women with type 2 diabetes (T2D) and obesity.
Materials and methods.
A group of 12 women aged 52-58 yr with T2D duration of 3-5 years, BMI 32-35 kg/m2, abnormally high C-peptide level,and НbА1с 7.5-8.5% were treated with 1500-2000 mg metformin/day and sulfonylureas at 50% of the maximum dose. Liraglutide was given insteadof sulfonylureas by a standard method (0.6 U/day for 1 week subcutaneously and 1.2 U/day thereafter). The total duration of therapy was 3 months.We analysed blood glucose level before and 2 hr after meals, НbА1с, lipidogram, C-peptide, HOMA index, BMI, waist circumference, percent of totalfat in the body, frequency of hypoglycemia, and side effects (nausea).
Results.
All patients achieved target values of НbА1с and a significant decrease in blood glucose before and after meals, body weight, total fat content,BMI, HOMA, systolic blood pressure; HDL cholesterol increased while LDL decreased. No case of hypoglycemia was documented. All the patientshad mild nausea of short duration (2-3 days).
Conclusion.
The use of liraglutide (Victoza) in women with T2D and obesity improve carbohydrate metabolism and insulin resistance without seriousside effects.
To study efficacy of treatment with liraglutide in women with type 2 diabetes (T2D) and obesity.
Materials and methods.
A group of 12 women aged 52-58 yr with T2D duration of 3-5 years, BMI 32-35 kg/m2, abnormally high C-peptide level,and НbА1с 7.5-8.5% were treated with 1500-2000 mg metformin/day and sulfonylureas at 50% of the maximum dose. Liraglutide was given insteadof sulfonylureas by a standard method (0.6 U/day for 1 week subcutaneously and 1.2 U/day thereafter). The total duration of therapy was 3 months.We analysed blood glucose level before and 2 hr after meals, НbА1с, lipidogram, C-peptide, HOMA index, BMI, waist circumference, percent of totalfat in the body, frequency of hypoglycemia, and side effects (nausea).
Results.
All patients achieved target values of НbА1с and a significant decrease in blood glucose before and after meals, body weight, total fat content,BMI, HOMA, systolic blood pressure; HDL cholesterol increased while LDL decreased. No case of hypoglycemia was documented. All the patientshad mild nausea of short duration (2-3 days).
Conclusion.
The use of liraglutide (Victoza) in women with T2D and obesity improve carbohydrate metabolism and insulin resistance without seriousside effects.
About the Authors
Vladimir Ivanovich Kudinov
Rostov Medical University, Rostov-on-Don
Natalya Vladimirovna Zolotareva
Rostov Medical University, Rostov-on-Don
Maria Sergeeva Nichitenko
Rostov Medical University, Rostov-on-Don
References
1. Дедов И.И., Шестакова М.В. Виктоза (Лираглутид): первый аналог человеческого ГПП-1 в лечении сахарного диабета 2-го типа. - М., 2010. - 46 с.
2. Шестакова М.В. Лираглутид: возможности комплексного терапевтического подхода в терапии сахарного диабета 2 типа // Сахарный диабет. Специальный выпуск. - 2010. - С. 3-6.
3. Галстян Г.Р. Клинические аспекты использования первого аналога человеческого глюкагоноподобного пептида 1 длительного действия - лираглутида при сахарном диабете 2 типа // Сахарный диабет. Специальный выпуск. - 2010. - С. 7-10.
Review
For citations:
Kudinov V.I., Zolotareva N.V., Nichitenko M.S. Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity. Diabetes mellitus. 2011;14(2):91-93. (In Russ.) https://doi.org/10.14341/2072-0351-5643
Views:
14738
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
